Document is current
Any future updates will be listed below
-
Authors
Elsman, Ellen B. M. http://orcid.org/0000-0002-0680-6430
Butcher, Nancy J.
Mokkink, Lidwine B.
Terwee, Caroline B.
Tricco, Andrea
Gagnier, Joel J.
Aiyegbusi, Olalekan Lee
Barnett, Carolina
Smith, Maureen
Moher, David
Offringa, Martin
-
Funding
Funding for this research was provided by:
Canadian Institutes of Health Research (452145)
- License Information
-
More Information
Article History
Received: 18 February 2022
Accepted: 28 May 2022
First Online: 13 June 2022
Declarations
:
: Not applicable
: Not applicable
: NB receives research funding from Canadian Institutes of Health Research, CHILD-BRIGHT, and the Cundill Centre for Child and Youth Depression. She also declares consulting fees from Nobias Therapeutics, Inc. LM and CT are one of the founders of the COSMIN initiative. OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC) West Midlands, Innovate UK (part of UK Research and Innovation), Janssen, Gilead, and GSK. OLA also declares personal fees from Gilead Sciences Ltd., GlaxoSmithKline (GSK) and Merck. CB has received funding from US Department of Defense, MGNet, Muscular Dystrophy Canada, Octapharma and Grifols. She has been consultant for Alexion, CSL, Sanofi, and Argenx. She is the primary developer of the MGII, and may receive royalties. The other authors declare that they have no competing interests.
